Skip to main content
. 2021 Dec 14;22(24):13421. doi: 10.3390/ijms222413421

Table 7.

Impact of treatment with antifibrotics on protein concentrations in serum from IPF patients. Patients were divided in three groups according to their treatment status at baseline and at follow-up. p-values calculated using Wilcoxon signed-rank test.

Protein Mean Change (±SD) Minimum Maximum p-Value
Untreated baseline and untreated follow-up
TRAIL −0.16 ± 0.19 −0.61 0.08 0.014
Untreated baseline and treated follow-up
EGF −0.92 ± 0.85 −2.21 0.85 0.003
TNFSF14 −0.75 ± 0.86 −1.87 1.47 0.011
CD40-L −0.67 ± 0.72 −1.88 0.59 0.011
CASP-8 −0.64 ± 0.56 −1.58 0.16 0.003
FGF2 −0.56 ± 0.45 −1.22 0.3 0.002
CCL3 −0.4 ± 0.38 −1.02 0.13 0.001
IL6 −0.35 ± 0.5 −1.47 0.25 0.033
MUC−16 −0.29 ± 0.38 −1.2 0.3 0.013
CD244 −0.27 ± 0.2 −0.58 0.14 0.001
GZMA −0.27 ± 0.28 −0.77 0.14 0.003
CD40 −0.26 ± 0.12 −0.46 −0.03 0.0002
LAMP3 −0.26 ± 0.37 −0.86 0.32 0.04
MCP-2 −0.25 ± 0.28 −0.95 0.07 0.006
KLRD1 −0.25 ± 0.24 −0.59 0.19 0.003
VEGFR-2 −0.24 ± 0.11 −0.41 −0.08 0.0002
IL18 −0.24 ± 0.29 −0.71 0.22 0.013
CCL4 −0.23 ± 0.24 −0.67 0.27 0.006
ADA −0.22 ± 0.22 −0.53 0.3 0.011
TWEAK −0.21 ± 0.15 −0.44 0.01 0.0005
CD28 −0.21 ± 0.27 −0.69 0.25 0.017
MIC-A/B −0.21 ± 0.23 −0.59 0.15 0.005
CCL23 −0.19 ± 0.28 −0.66 0.34 0.04
TIE2 −0.18 ± 0.12 −0.42 0 0.0005
FASLG −0.17 ± 0.13 −0.45 0 0.0005
TRAIL −0.14 ± 0.21 −0.62 0.14 0.022
KIR3DL1 −0.14 ± 0.18 −0.45 0.15 0.017
ICOSLG −0.1 ± 0.15 −0.3 0.17 0.04
PD-L2 −0.1 ± 0.17 −0.34 0.32 0.048
TNFRSF21 −0.08 ± 0.13 −0.33 0.17 0.027
IL10 0.21 ± 0.32 −0.39 0.75 0.033
Treated baseline and treated follow-up
FGF2 −0.31 ± 0.28 −0.83 0.08 0.003
CD28 −0.09 ± 0.15 −0.32 0.11 0.043
CD244 −0.08 ± 0.12 −0.23 0.12 0.027
ICOSLG −0.06 ± 0.09 −0.2 0.14 0.043
CD8A 0.18 ± 0.19 −0.11 0.58 0.009
MMP12 0.27 ± 0.45 −0.68 1.05 0.043
GZMB 0.33 ± 0.47 −0.12 1.37 0.021
PTN 0.53 ± 0.53 −0.42 1.28 0.007